[1] Ott JJ, Stevens GA, Groeger J, et al. Global epidemiology of hepatitisB virus infection:new estimates of age-specific HBsAg seroprevalence and endemicity.Vaccine,2012,30:2212-2219.
[2] 中华医学会肝病学分会,中华医学会感染病学分会.慢性乙型肝炎防治指南(2015 年版). 中国肝脏病杂志,2015,7: 1-17.
[3] Torre LA, Bray F,Siegel RL,et al. Global cancer statistics,2012.CA Cancer J Clin,2015,65: 87-108.
[4] Chen W,Zheng R,Baade PD,et al. Cancer statistics in China,2015.CA Cancer J Clin,2016,66: 115-132.
[5] 杨婉婷,侯恩存.原发性肝癌治疗的研究进展. 现代肿瘤医学,2016,24: 3495-3499.
[6] 汤钊猷.现代肿瘤学(第3版).复旦大学出版社,2014: 891-934.
[7] Bruix J,Sherman M. American association for the study of liver diseases. Management of hepatocellular carcinoma:an update. Hepatology,2011,53: 1020-1022.
[8] Badawy AA,El-Hindawi A,Hammam O,et al. Impact of epidermal growth factor receptor and transforming growth factor-α on hepatitis C virus-induced hepatocarcinogenesis.APMIS,2015,123: 823-831.
[9] Qiao Q, Zhang J, Wang W, et al. Over-expression of transforming growth factor-alpha and epidermal growth factor receptor in human hepatic cirrhosis tissues. Hepatogastroenterology, 2008, 55: 169-172.
[10] Tsai W, Lee H, Jin J, et al.Association between osteopontin and EGFR expression with clinicopathological parameters in hepatocellular carcinoma. Chin J Physiol, 2012, 55:412-420.
[11] Berasain C, Castillo J, Prieto J, et al. New molecular targets for hepatocellular carcinoma: the ErbB1 signaling system. Liver Int, 2007, 27:174-185.
[12] Balkwill FR,Mantovani A. Cancer-related inflammation: common themes and therapeutic opportunities. Semin Cancer Biol,2012,22: 33-40.
[13] Cuevas M, Tieppo J, Marroni N, et al. Suppression of amphiregulin/epidermal growth factor receptor signals contributes to the protective effects of quercetin in cirrhotic liver. J Nutr, 2011, 141:1299-1305.
[14] Berasain C, Perugorria M, Latasa M, et al. The epidermal growth factor receptor: a link between inflammation and liver cancer. Exp Biol Med, 2009, 234: 713-725.
[15] El-Bassiouni A, Nosseir M, Zoheiry M, et al. Immunohistochemical expression of CD95 (Fas), c-myc and epidermal growth factor receptor in hepatitis C virus infection,cirrhotic liver disease and hepatocellular carcinoma. APMIS, 2006, 114: 420-427.
[16] Ito Y, Takeda T, Sakon M, et al. Expression and clinical significance of erb-B receptor family in hepatocellular carcinoma. Br J Cancer, 2001, 84: 1377-1383.
[17] Freed DM,Bessman NJ,Kiyatkin A,et al. EGFR ligands differen-tially stabilize receptor dimers to specify signaling kinetics. Cell, 2017, 4: S0092-8674.
[18] Yarden Y, Sliwkowski MX. Untangling the ErbB signaling network. Nat Rev Mol Cell Biol, 2001, 2: 127-137.
[19] 王涛, 王人颢. 表皮生长因子受体与肝癌发病机制及靶向治疗的研究进展. 2017, 9: 327-329.
[20] Lindsey S,Langhans SA. Epidermal growth factor signaling in transformed cells. Int Rev Cell Mol Biol,2015,314:1-41.
[21] Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med, 2008, 359: 378-390.
[22] Philip PA, Mahoney MR, Allmer C, et al. Phase II study of Erlotinib (OSI-774) in patients with advanced hepatocellular cancer. J Clin Oncol, 2005, 23: 6657-6663
[23] Asnacios A, Fartoux L, Romano O, et al. Gemcitabine plus oxaliplatin (GEMOX) combined with cetuximab in patients with progressive advanced stage hepatocellular carcinoma: results of a multicenter phase 2 study. Cancer, 2008, 112: 2733-2739. |
